AR123862A1 - Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares - Google Patents

Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares

Info

Publication number
AR123862A1
AR123862A1 ARP210102899A ARP210102899A AR123862A1 AR 123862 A1 AR123862 A1 AR 123862A1 AR P210102899 A ARP210102899 A AR P210102899A AR P210102899 A ARP210102899 A AR P210102899A AR 123862 A1 AR123862 A1 AR 123862A1
Authority
AR
Argentina
Prior art keywords
variable domain
chain variable
seq
amino acid
acid sequence
Prior art date
Application number
ARP210102899A
Other languages
English (en)
Inventor
Peter Michael Benz
Remko Alexander Bakker
Holger Fuchs
Fei Han
Sandeep Kumar
Sarah Low
Justin M Scheer
Leo Thomas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR123862A1 publication Critical patent/AR123862A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Moléculas de unión que se unen específicamente al factor de crecimiento endotelial vascular (VEGF) y al receptor quinasa B de la tropomiosina (TrkB) y a su uso en medicina, composiciones farmacéuticas que lo comprenden y métodos para su uso como agentes para el tratamiento y/o prevención de enfermedades oculares. Reivindicación 1: Una molécula de unión caracterizada porque comprende al menos un sitio de unión al antígeno que se une específicamente al factor de crecimiento endotelial vascular (VEGF) y al menos un sitio de unión al antígeno que se une específicamente al receptor quinasa B de la tropomiosina (TrkB). Reivindicación 28: Un scFv que se une específicamente a TrkB que comprende (i) un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 213 y un dominio variable de cadena pesada caracterizado porque comprende la secuencia de aminoácidos de SEQ ID Nº 214, o (ii) un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 215 y un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 216. Reivindicación 30: Una molécula de anticuerpo que se une específicamente a VEGF caracterizada porque comprende: (i) un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 189, y un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 191; o un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 192; o un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 194; (ii) un dominio variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 190, y un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 192; o un dominio variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID Nº 193. Reivindicación 32: Una molécula de ácido nucleico aislada caracterizada porque codifica (i) la cadena pesada o el dominio variable de la cadena pesada y/o (ii) la cadena ligera o el dominio variable de la cadena ligera de una molécula de unión de acuerdo con cualquiera de las reivindicaciones 1 a 19. Reivindicación 36: Un vector viral caracterizado porque comprende la molécula de ácido nucleico aislada de acuerdo con cualquiera de las reivindicaciones 32 a 35. Reivindicación 37: Un vector de expresión caracterizado porque comprende una molécula de ácido nucleico de acuerdo con cualquiera de las reivindicaciones 32 a 35. Reivindicación 38: Una célula huésped caracterizada porque está transfectada con un vector de expresión de acuerdo con la reivindicación 37. Reivindicación 39: Un método de fabricación de una molécula de unión de acuerdo con las reivindicaciones 1 a 19, una molécula de unión de TrkB de acuerdo con las reivindicaciones 20 a 27, un scFv de acuerdo con las reivindicaciones 28 a 29 o una molécula de anticuerpo de acuerdo con las reivindicaciones 30 a 31, caracterizado porque comprende (a) cultivar la célula huésped de acuerdo con la reivindicación 38 en condiciones que permitan la expresión de la molécula; y, (b) recuperar la molécula; y opcionalmente (c) purificar y/o modificar y/o formular adicionalmente la molécula. Reivindicación 47: Una composición farmacéutica caracterizada porque comprende un portador farmacéuticamente aceptable y la molécula de unión de acuerdo con cualquiera de las reivindicaciones 1 a 19, la molécula de unión de TrkB de acuerdo con las reivindicaciones 20 a 27, el scFv de acuerdo con las reivindicaciones 28 a 29, o la molécula de anticuerpo de acuerdo con las reivindicaciones 30 al 31.
ARP210102899A 2020-10-21 2021-10-20 Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares AR123862A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20203030 2020-10-21

Publications (1)

Publication Number Publication Date
AR123862A1 true AR123862A1 (es) 2023-01-18

Family

ID=73005392

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102899A AR123862A1 (es) 2020-10-21 2021-10-20 Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares

Country Status (7)

Country Link
US (2) US20220119536A1 (es)
EP (2) EP4232476A2 (es)
JP (2) JP2023546229A (es)
CN (2) CN117043186A (es)
AR (1) AR123862A1 (es)
TW (1) TW202233668A (es)
WO (2) WO2022084354A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546229A (ja) * 2020-10-21 2023-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼の疾患の処置のためのアゴニスト性TrkB結合分子

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
EP1945671A2 (en) 2005-10-12 2008-07-23 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
WO2008058127A2 (en) 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
UY33707A (es) * 2010-11-04 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック, インコーポレイテッド 抗vegf抗体の最適化変異体
CN109414501A (zh) 2016-05-03 2019-03-01 斯克利普斯研究院 用于治疗神经退行性疾病的TrkB激动剂抗体
AU2017324983A1 (en) 2016-09-07 2019-04-18 Saksin Lifesciences Pvt Ltd Synthetic antibodies against VEGF and their uses
JP7216424B2 (ja) 2017-03-15 2023-02-01 チンファ ユニバーシティ 新規の抗TrkB抗体
PE20191758A1 (es) 2017-03-22 2019-12-12 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
US20220185875A1 (en) 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
JP2020187202A (ja) 2019-05-13 2020-11-19 キヤノン株式会社 画像形成装置
JP2023546229A (ja) 2020-10-21 2023-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼の疾患の処置のためのアゴニスト性TrkB結合分子

Also Published As

Publication number Publication date
EP4232476A2 (en) 2023-08-30
CN117043186A (zh) 2023-11-10
WO2022084355A2 (en) 2022-04-28
US20220119535A1 (en) 2022-04-21
CN116829586A (zh) 2023-09-29
US20220119536A1 (en) 2022-04-21
US12110335B2 (en) 2024-10-08
TW202233668A (zh) 2022-09-01
JP2023546229A (ja) 2023-11-01
WO2022084354A1 (en) 2022-04-28
JP2023546228A (ja) 2023-11-01
WO2022084355A3 (en) 2022-06-02
EP4232474A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
AR102592A1 (es) Anticuerpos biespecíficos y métodos de uso en oftalmología
RU2015150149A (ru) Составы на основе биспецифических антител к il-4/il-13
HRP20210736T1 (hr) Protutijela anti-htra1 i načini njihove uporabe
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
AR123862A1 (es) Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares
RU2020121533A (ru) Антагонисты ildr2 и их комбинации
PE20240913A1 (es) Anticuerpos anti-il-2r agonistas y metodos de uso
AR123306A1 (es) Anticuerpos fgfr3 y métodos de uso
PE20231080A1 (es) Anticuerpos que se unen a cd3 y cd19
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
AR125488A1 (es) Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas
AR125142A1 (es) Moléculas de unión terapéuticas
CN112996564A (zh) 靶向il-1r1和nlpr3的双特异性抗体
US10370442B2 (en) vNAR recombinant monoclonal antibodies that neutralize vascular endophelial growth factor VEGF
MX2022000780A (es) Fragmento fab del anticuerpo anti-vegf humanizado y uso del mismo.
AR125857A1 (es) ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS
RU2016135418A (ru) Новый анализ для детектирования периостина человека
PE20240086A1 (es) Anticuerpos anti-cd122 y usos de estos
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
PE20230414A1 (es) Agentes de fijacion a tie2 y metodos de uso
KR20240016991A (ko) 항-nkg2a 항체 및 조성물
AR122286A1 (es) Anticuerpos potenciadores del factor h y usos de estos